MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.

J Transl Med · 2012 · PMC3311573 · PMID 22390413

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

The observed difference at 24 months was significant based on the pyrosequencing results but only borderline significant based on the qMSP results.

also in 11,409 other papers

showed a trendno p-value reported

These results are in line with the observation that the patients with non-concordant methylation findings (unmethylated by qMSP and methylated by pyrosequencing) showed a trend towards better survival than patients with unmethylated MGMT promoter by both methods (Figure 1C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.